{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T06:36:10Z","timestamp":1792910170506,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-13054-5","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:54:08Z","timestamp":1792763648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers and future directions for immunotherapy in microsatellite-stable colorectal cancer: a systematic review"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-0920","authenticated-orcid":false,"given":"Jiaju","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0185-1534","authenticated-orcid":false,"given":"Chunxiao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6831-2964","authenticated-orcid":false,"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6237-842X","authenticated-orcid":false,"given":"Lidong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"1","key":"13054_CR1","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1186\/s12885-025-15138-0","volume":"25","author":"S Wu","year":"2025","unstructured":"Wu S, Zhang Y, Lin Z, Wei M (2025) Global burden of colorectal cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. BMC Cancer 25(1):1770. https:\/\/doi.org\/10.1186\/s12885-025-15138-0","journal-title":"BMC Cancer"},{"issue":"2","key":"13054_CR2","doi-asserted-by":"publisher","first-page":"111315","DOI":"10.1016\/j.ejso.2025.111315","volume":"52","author":"SH Emile","year":"2026","unstructured":"Emile SH, Horesh N, Wignakumar A, Boutros M, Wexner SD (2026) Advanced T stage and nodal disease are independently associated with worse cancer-specific survival in stage IV colorectal cancer: A SEER-based survival analysis. Eur J Surg oncology: J Eur Soc Surg Oncol Br Association Surg Oncol 52(2):111315. https:\/\/doi.org\/10.1016\/j.ejso.2025.111315","journal-title":"Eur J Surg oncology: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"5","key":"13054_CR3","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","volume":"29","author":"DC Guven","year":"2024","unstructured":"Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A et al (2024) The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review. Oncologist 29(5):e580\u2013e600. https:\/\/doi.org\/10.1093\/oncolo\/oyae013","journal-title":"Oncologist"},{"issue":"1","key":"13054_CR4","doi-asserted-by":"publisher","first-page":"104108","DOI":"10.1016\/j.esmoop.2024.104108","volume":"10","author":"K Yamaguchi","year":"2025","unstructured":"Yamaguchi K, Tsuchihashi K, Ueno S, Uehara K, Taguchi R, Ito M et al (2025) Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes. ESMO open 10(1):104108. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104108","journal-title":"ESMO open"},{"issue":"12","key":"13054_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","volume":"25","author":"KB Kennel","year":"2025","unstructured":"Kennel KB, Greten FR (2025) The immune microenvironment of colorectal cancer. Nat Rev Cancer 25(12):945\u2013964. https:\/\/doi.org\/10.1038\/s41568-025-00872-1","journal-title":"Nat Rev Cancer"},{"issue":"38","key":"13054_CR6","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/s41388-023-02806-3","volume":"42","author":"D Zhang","year":"2023","unstructured":"Zhang D, Ni QQ, Liang QY, He LL, Qiu BW, Zhang LJ et al (2023) ASCL2 induces an immune excluded microenvironment by activating cancer-associated fibroblasts in microsatellite stable colorectal cancer. Oncogene 42(38):2841\u20132853. https:\/\/doi.org\/10.1038\/s41388-023-02806-3","journal-title":"Oncogene"},{"key":"13054_CR7","doi-asserted-by":"publisher","first-page":"1757513","DOI":"10.3389\/fimmu.2026.1757513","volume":"17","author":"W Zhang","year":"2026","unstructured":"Zhang W, Jin C, Liu S, Wan X, Li Y, Liu J et al (2026) Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. Front Immunol 17:1757513. https:\/\/doi.org\/10.3389\/fimmu.2026.1757513","journal-title":"Front Immunol"},{"issue":"3","key":"13054_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1158\/0008-5472.CAN-25-0079","volume":"86","author":"JD Fumet","year":"2026","unstructured":"Fumet JD, Latour C, Nuttin L, Derangere V, Ilie A, Russo P et al (2026) Tumor-Associated Macrophages Produce PGE2 to Promote CD8\u2009+\u2009T-cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite-Stable Colorectal Cancer. Cancer Res 86(3):785\u2013801. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-0079","journal-title":"Cancer Res"},{"issue":"2","key":"13054_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C et al (2023) Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut 72(2):325\u2013337. https:\/\/doi.org\/10.1136\/gutjnl-2021-325808","journal-title":"Gut"},{"key":"13054_CR10","doi-asserted-by":"publisher","unstructured":"Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP et al (2021) Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci USA 118(45). https:\/\/doi.org\/10.1073\/pnas.2105323118","DOI":"10.1073\/pnas.2105323118"},{"key":"13054_CR11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK et al (2024) Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network: JNCCN. https:\/\/doi.org\/10.6004\/jnccn.2024.0029. 22(2 D)","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"1","key":"13054_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12885-020-07169-6","volume":"20","author":"C Antoniotti","year":"2020","unstructured":"Antoniotti C, Borelli B, Rossini D, Pietrantonio F, Morano F, Salvatore L et al (2020) AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer 20(1):683. https:\/\/doi.org\/10.1186\/s12885-020-07169-6","journal-title":"BMC Cancer"},{"key":"13054_CR13","doi-asserted-by":"publisher","unstructured":"Middleton G, Gaskell C, Savage J, Bridgewater J, Ross P, Saunders M et al (2025) Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1. J Immunother Cancer 13(12). https:\/\/doi.org\/10.1136\/jitc-2025-012749","DOI":"10.1136\/jitc-2025-012749"},{"key":"13054_CR14","doi-asserted-by":"publisher","unstructured":"DeVito NC, Fakih MG, Randolph Hecht J, Parikh AR, Bekaii-Saab T, Xie H et al (2025) 541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697). J Immunother Cancer 13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0541","DOI":"10.1136\/jitc-2025-SITC2025.0541"},{"key":"13054_CR15","doi-asserted-by":"crossref","unstructured":"Bayo C, Mar\u00edn S, Madurga S, Lahoz S, Archilla I, Bravo R et al (2025) Metabolic plasticity underlying resistance to anti-PD1 retifanlimab and the arginase inhibitor CB-1158, in microsatellite-stable colorectal cancer patient-derived organoids co-cultured with tumor-infiltrating lymphocytes. Research Square","DOI":"10.21203\/rs.3.rs-6724351\/v1"},{"issue":"4","key":"13054_CR16","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000521332","volume":"45","author":"K Schenck","year":"2022","unstructured":"Schenck K, Masetti M, Pfarr N, Lorenzen S (2022) PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation. Oncol Res Treat 45(4):222\u2013226. https:\/\/doi.org\/10.1159\/000521332","journal-title":"Oncol Res Treat"},{"issue":"6","key":"13054_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-25-2566","volume":"32","author":"C Yeh","year":"2026","unstructured":"Yeh C, Artz O, Zhang H, Karnoub ER, Ntiamoah P, Weipert C et al (2026) Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer. Clin cancer research: official J Am Association Cancer Res 32(6):1100\u20131109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2566","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"9","key":"13054_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/mc.23562","volume":"62","author":"Y Lin","year":"2023","unstructured":"Lin Y, Luo S, Luo M, Lu X, Li Q, Xie M et al (2023) Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors. Mol Carcinog 62(9):1271\u20131283. https:\/\/doi.org\/10.1002\/mc.23562","journal-title":"Mol Carcinog"},{"issue":"2","key":"13054_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jnci\/djab169","volume":"114","author":"R Moretto","year":"2022","unstructured":"Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V et al (2022) Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. J Natl Cancer Inst 114(2):271\u2013279. https:\/\/doi.org\/10.1093\/jnci\/djab169","journal-title":"J Natl Cancer Inst"},{"key":"13054_CR20","doi-asserted-by":"publisher","unstructured":"Song M, Zeng X, Wu Q, Huang J, Dong J, Shao L et al (2023) Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature. Life 13(5). https:\/\/doi.org\/10.3390\/life13051183","DOI":"10.3390\/life13051183"},{"issue":"5","key":"13054_CR21","doi-asserted-by":"publisher","first-page":"102767","DOI":"10.4251\/wjgo.v17.i5.102767","volume":"17","author":"H Feng","year":"2025","unstructured":"Feng H, Zhao LY, Xu Z, Xie QF, Deng HJ, Yu J et al (2025) Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China. World J Gastrointest Oncol 17(5):102767. https:\/\/doi.org\/10.4251\/wjgo.v17.i5.102767","journal-title":"World J Gastrointest Oncol"},{"key":"13054_CR22","doi-asserted-by":"publisher","first-page":"1039631","DOI":"10.3389\/fimmu.2022.1039631","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Xiao H, Cui L, Fang L, Han S, Ruan Y et al (2022) Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer. Front Immunol 13:1039631. https:\/\/doi.org\/10.3389\/fimmu.2022.1039631","journal-title":"Front Immunol"},{"issue":"1","key":"13054_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12876-025-03968-y","volume":"25","author":"M Deng","year":"2025","unstructured":"Deng M, Li X, Wu H, Xue D, Wang Y, Guo R et al (2025) The current status and prospects of gut microbiota combined with PD-1\/PD-L1 inhibitors in the treatment of colorectal cancer: a review. BMC Gastroenterol 25(1):380. https:\/\/doi.org\/10.1186\/s12876-025-03968-y","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"13054_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/1078-0432.ccr-25-2160","volume":"32","author":"ME Salem","year":"2026","unstructured":"Salem ME, Puccini A, Mauer E, Andr\u00e9 T, George TJ, Tabernero J et al (2026) Impact of RAS\/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair\u2013Deficient\/Microsatellite Instability Colorectal Cancers. Clin Cancer Res 32(2):417\u2013427. https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-2160","journal-title":"Clin Cancer Res"},{"issue":"11","key":"13054_CR25","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.ccell.2025.08.002","volume":"43","author":"VK Morris","year":"2025","unstructured":"Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A et al (2025) Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF(V600E) metastatic colorectal cancer. Cancer Cell 43(11):2106\u201318e3. https:\/\/doi.org\/10.1016\/j.ccell.2025.08.002","journal-title":"Cancer Cell"},{"issue":"1","key":"13054_CR26","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1038\/s41598-023-31538-3","volume":"13","author":"P Ziranu","year":"2023","unstructured":"Ziranu P, Pretta A, Pozzari M, Maccioni A, Badiali M, Fanni D et al (2023) CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. Sci Rep 13(1):4397. https:\/\/doi.org\/10.1038\/s41598-023-31538-3","journal-title":"Sci Rep"},{"issue":"2","key":"13054_CR27","doi-asserted-by":"publisher","first-page":"104135","DOI":"10.1016\/j.esmoop.2025.104135","volume":"10","author":"C Antoniotti","year":"2025","unstructured":"Antoniotti C, Carullo M, Rossini D, Pietrantonio F, Salvatore L, Lonardi S et al (2025) Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study. ESMO open 10(2):104135. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104135","journal-title":"ESMO open"},{"issue":"1","key":"13054_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12943-024-02166-w","volume":"23","author":"Q Xie","year":"2024","unstructured":"Xie Q, Liu X, Liu R, Pan J, Liang J (2024) Cellular mechanisms of combining innate immunity activation with PD-1\/PD-L1 blockade in treatment of colorectal cancer. Mol Cancer 23(1):252. https:\/\/doi.org\/10.1186\/s12943-024-02166-w","journal-title":"Mol Cancer"},{"issue":"11","key":"13054_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C et al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21(11):1350\u20131356. https:\/\/doi.org\/10.1038\/nm.3967","journal-title":"Nat Med"},{"key":"13054_CR30","doi-asserted-by":"publisher","unstructured":"Dienstmann R, Connor K, Byrne AT (2020) Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology 158(4). https:\/\/doi.org\/10.1053\/j.gastro.2019.12.051","DOI":"10.1053\/j.gastro.2019.12.051"},{"issue":"12","key":"13054_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11864-021-00913-5","volume":"22","author":"J Ros","year":"2021","unstructured":"Ros J, Baraibar I, Martini G, Salva F, Saoudi N, Cuadra-Urteaga JL et al (2021) The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 22(12):113. https:\/\/doi.org\/10.1007\/s11864-021-00913-5","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"13054_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41416-024-02826-0","volume":"131","author":"S Chowdhury","year":"2024","unstructured":"Chowdhury S, Xiu J, Ribeiro JR, Nicolaides T, Zhang J, Korn WM et al (2024) Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br J Cancer 131(8):1328\u20131339. https:\/\/doi.org\/10.1038\/s41416-024-02826-0","journal-title":"Br J Cancer"},{"issue":"1","key":"13054_CR33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13059-022-02677-z","volume":"23","author":"AM Khaliq","year":"2022","unstructured":"Khaliq AM, Erdogan C, Kurt Z, Turgut SS, Grunvald MW, Rand T et al (2022) Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biol 23(1):113. https:\/\/doi.org\/10.1186\/s13059-022-02677-z","journal-title":"Genome Biol"},{"issue":"16suppl","key":"13054_CR34","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1200\/JCO.2025.43.16_suppl.3573","volume":"43","author":"M Lim","year":"2025","unstructured":"Lim M, Lin K, Abdelfattah N, Parseghian C, Morelli MP, Willis J et al (2025) Clinicopathologic features of complement activation signatures in colorectal cancer. J Clin Oncol 43(16suppl):3573. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3573","journal-title":"J Clin Oncol"},{"issue":"15","key":"13054_CR35","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-24-0268","volume":"30","author":"JM Loree","year":"2024","unstructured":"Loree JM, Titmuss E, Topham JT, Kennecke HF, Feilotter H, Virk S et al (2024) Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clin cancer research: official J Am Association Cancer Res 30(15):3189\u20133199. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0268","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"8","key":"13054_CR36","doi-asserted-by":"publisher","first-page":"e1003741","DOI":"10.1371\/journal.pmed.1003741","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yang L, Bao H, Fan X, Xia F, Wan J et al (2021) Utility of Ctdna in Predicting Response to Neoadjuvant Chemoradiotherapy and Prognosis Assessment in Locally Advanced Rectal Cancer: A Prospective Cohort Study. PLoS Med 18(8):e1003741. https:\/\/doi.org\/10.1371\/journal.pmed.1003741","journal-title":"PLoS Med"},{"key":"13054_CR37","doi-asserted-by":"publisher","unstructured":"Saeed A, Yothers G, Puhalla SL, Tojjari A, Rastogi P, Freeman TJ et al (2026) EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease. Future Oncol 1\u20139. https:\/\/doi.org\/10.1080\/14796694.2026.2688569","DOI":"10.1080\/14796694.2026.2688569"},{"key":"13054_CR38","doi-asserted-by":"publisher","first-page":"104775","DOI":"10.1016\/j.critrevonc.2025.104775","volume":"212","author":"E Chen","year":"2025","unstructured":"Chen E, Zhou W (2025) Immunotherapy in Microsatellite-Stable Colorectal Cancer: Strategies to Overcome Resistance. Crit Rev Oncol\/Hematol 212:104775. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104775","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"12","key":"13054_CR39","doi-asserted-by":"publisher","first-page":"e2346094","DOI":"10.1001\/jamanetworkopen.2023.46094","volume":"6","author":"EX Chen","year":"2023","unstructured":"Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S et al (2023) Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw open 6(12):e2346094. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.46094","journal-title":"JAMA Netw open"},{"key":"13054_CR40","doi-asserted-by":"publisher","first-page":"113437","DOI":"10.1016\/j.ejca.2023.113437","volume":"196","author":"M Fakih","year":"2024","unstructured":"Fakih M, Wang C, Sandhu J, Ye J, Egelston C, Li X (2024) Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur J Cancer 196:113437. https:\/\/doi.org\/10.1016\/j.ejca.2023.113437","journal-title":"Eur J Cancer"},{"issue":"8","key":"13054_CR41","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/ijc.32856","volume":"146","author":"J Di","year":"2020","unstructured":"Di J, Liu M, Fan Y, Gao P, Wang Z, Jiang B et al (2020) Phenotype molding of T cells in colorectal cancer by single-cell analysis. Int J Cancer 146(8):2281\u20132295. https:\/\/doi.org\/10.1002\/ijc.32856","journal-title":"Int J Cancer"},{"issue":"6","key":"13054_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","volume":"22","author":"M Mittelbrunn","year":"2021","unstructured":"Mittelbrunn M, Kroemer G (2021) Hallmarks of T cell aging. Nat Immunol 22(6):687\u2013698. https:\/\/doi.org\/10.1038\/s41590-021-00927-z","journal-title":"Nat Immunol"},{"issue":"5","key":"13054_CR43","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","volume":"7","author":"CM Kim","year":"2022","unstructured":"Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS (2022) The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO open 7(5):100577. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100577","journal-title":"ESMO open"},{"issue":"3","key":"13054_CR44","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T et al (2016) L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell 167(3):829\u2013842. https:\/\/doi.org\/10.1016\/j.cell.2016.09.031","journal-title":"Cell"},{"key":"13054_CR45","doi-asserted-by":"publisher","unstructured":"Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L et al (2019) Targeting the Arginine Metabolic Brake Enhances Immunotherapy for Leukaemia. Int J Cancer 145(8). https:\/\/doi.org\/10.1002\/ijc.32028","DOI":"10.1002\/ijc.32028"},{"issue":"1","key":"13054_CR46","doi-asserted-by":"publisher","first-page":"1956143","DOI":"10.1080\/2162402x.2021.1956143","volume":"10","author":"A Sosnowska","year":"2021","unstructured":"Sosnowska A, Chlebowska-Tuz J, Matryba P, Pilch Z, Greig A, Wolny A et al (2021) Inhibition of Arginase Modulates T-cell Response in the Tumor Microenvironment of Lung Carcinoma. Oncoimmunology 10(1):1956143. https:\/\/doi.org\/10.1080\/2162402x.2021.1956143","journal-title":"Oncoimmunology"},{"key":"13054_CR47","doi-asserted-by":"publisher","unstructured":"Vonwirth V, Buelbuel Y, Werner A, Echchannaoui H, Windschmitt J, Habermeier A et al (2021) Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.617699","DOI":"10.3389\/fimmu.2020.617699"},{"key":"13054_CR48","doi-asserted-by":"publisher","unstructured":"Ma LX, Titmuss E, Loree JM, Jonker DJ, Kennecke HF, Berry S et al (2024) Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial. J Immunother Cancer 12(12). https:\/\/doi.org\/10.1136\/jitc-2024-010094","DOI":"10.1136\/jitc-2024-010094"},{"key":"13054_CR49","doi-asserted-by":"publisher","first-page":"104342","DOI":"10.1016\/j.critrevonc.2024.104342","volume":"197","author":"A Marques","year":"2024","unstructured":"Marques A, Cavaco P, Torre C, Sepodes B, Rocha J (2024) Tumor mutational burden in colorectal cancer: Implications for treatment. Crit Rev Oncol\/Hematol 197:104342. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104342","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"2","key":"13054_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1470-2045(22)00783-5","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F et al (2023) Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol 24(2):151\u2013161. https:\/\/doi.org\/10.1016\/S1470-2045(22)00783-5","journal-title":"Lancet Oncol"},{"key":"13054_CR51","doi-asserted-by":"publisher","unstructured":"Yamaguchi K, Tsuchihashi K, Ueno S, Uehara K, Taguchi R, Ito M et al (2025) Efficacy of Pembrolizumab in Microsatellite-Stable, Tumor Mutational Burden-High Metastatic Colorectal Cancer: Genomic Signatures and Clinical Outcomes. ESMO open 10(1). https:\/\/doi.org\/10.1016\/j.esmoop.2024.104108","DOI":"10.1016\/j.esmoop.2024.104108"},{"issue":"10","key":"13054_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","volume":"2","author":"PMK Westcott","year":"2021","unstructured":"Westcott PMK, Sacks NJ, Schenkel JM, Ely ZA, Smith O, Hauck H et al (2021) Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat cancer 2(10):1071\u20131085. https:\/\/doi.org\/10.1038\/s43018-021-00247-z","journal-title":"Nat cancer"},{"issue":"12","key":"13054_CR53","doi-asserted-by":"publisher","first-page":"105892","DOI":"10.1016\/j.esmoop.2025.105892","volume":"10","author":"E Elez","year":"2025","unstructured":"Elez E, Siena S, Sartore-Bianchi A, Ros J, Ciardello F, Martinelli E et al (2025) Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. ESMO open 10(12):105892. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105892","journal-title":"ESMO open"},{"issue":"2","key":"13054_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clcc.2024.03.002","volume":"23","author":"EX Chen","year":"2024","unstructured":"Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG et al (2024) Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS\/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer 23(2):183\u2013193. https:\/\/doi.org\/10.1016\/j.clcc.2024.03.002","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"13054_CR55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12885-024-12153-5","volume":"24","author":"E Elez","year":"2024","unstructured":"Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B et al (2024) Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b\/2 study. BMC Cancer 24(1):446. https:\/\/doi.org\/10.1186\/s12885-024-12153-5","journal-title":"BMC Cancer"},{"issue":"17","key":"13054_CR56","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1158\/1078-0432.CCR-24-0090","volume":"30","author":"RW Lentz","year":"2024","unstructured":"Lentz RW, Friedrich TJ, Blatchford PJ, Jordan KR, Pitts TM, Robinson HR et al (2024) A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. Clin cancer research: official J Am Association Cancer Res 30(17):3768\u20133778. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0090","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"13054_CR57","doi-asserted-by":"publisher","unstructured":"Liu Y, Erbe R, Jin A, Zander AD, Hyun SW, Stein MM et al (2025) 134 A multi-omic immune profile score (IPS) stratifies real-world outcomes of microsatellite stable (MSS) advanced colorectal cancer patients treated with immune checkpoint inhibitors. J Immunother Cancer 13(Suppl 2). https:\/\/doi.org\/10.1136\/jitc-2025-SITC2025.0134","DOI":"10.1136\/jitc-2025-SITC2025.0134"},{"key":"13054_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336804","author":"M Iglesias Coma","year":"2026","unstructured":"Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C, Linares J, Tarazona N, Mulet-Margalef N et al (2026) Stromal biomarker-based framework for identifying pMMR\/MSS and dMMR\/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2025-336804","journal-title":"Gut"},{"key":"13054_CR59","doi-asserted-by":"publisher","unstructured":"Incognito D, Ciappina G, Gelsomino C, Picone A, Consolo P, Scano A et al (2025) Fusobacterium Nucleatum in Colorectal Cancer: Relationship Among Immune Modulation, Potential Biomarkers and Therapeutic Implications. Int J Mol Sci 26(19). https:\/\/doi.org\/10.3390\/ijms26199710","DOI":"10.3390\/ijms26199710"},{"issue":"18","key":"13054_CR60","doi-asserted-by":"publisher","first-page":"e37511","DOI":"10.1016\/j.heliyon.2024.e37511","volume":"10","author":"T Ding","year":"2024","unstructured":"Ding T, Chen Q, Liu H, Zhang H, Sun Y, Zhao L et al (2024) Single-cell RNA sequencing analysis reveals the distinct features of colorectal cancer with or without Fusobacterium nucleatum infection in PD-L1 blockade therapy. Heliyon 10(18):e37511. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37511","journal-title":"Heliyon"},{"issue":"4","key":"13054_CR61","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s10637-025-01573-0","volume":"43","author":"JS Wang","year":"2025","unstructured":"Wang JS, Arrowsmith ER, Beck JT, Friedmann J, Jamal R, McHale D et al (2025) Phase 1\/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors. Investig New Drugs 43(4):894\u2013903. https:\/\/doi.org\/10.1007\/s10637-025-01573-0","journal-title":"Investig New Drugs"},{"key":"13054_CR62","doi-asserted-by":"publisher","first-page":"1803929","DOI":"10.3389\/fmed.2026.1803929","volume":"13","author":"H Chen","year":"2026","unstructured":"Chen H, Xia Z, Shen Y, Xie X, Qiu M, Lin M et al (2026) Systemic nutritional status and its dynamic changes as predictors of response to neoadjuvant immunotherapy in locally advanced MSS\/pMMR colorectal cancer. Front Med 13:1803929. https:\/\/doi.org\/10.3389\/fmed.2026.1803929","journal-title":"Front Med"},{"key":"13054_CR63","doi-asserted-by":"publisher","first-page":"877635","DOI":"10.3389\/fonc.2022.877635","volume":"12","author":"J Lang","year":"2022","unstructured":"Lang J, Leal AD, Marin-Jimenez JA, Hartman SJ, Shulman J, Navarro NM et al (2022) Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. Front Oncol 12:877635. https:\/\/doi.org\/10.3389\/fonc.2022.877635","journal-title":"Front Oncol"},{"key":"13054_CR64","doi-asserted-by":"publisher","unstructured":"Garralda E, Joerger M, Gutierrez M, Garcia VM, Santoro A, Chandana S et al (2025) A Phase I Study of INCA33890, a PD-1\/TGF\u03b2R2 Bispecific Antibody, for Advanced Solid Tumours. J Thorac Oncol 36. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2153","DOI":"10.1016\/j.annonc.2025.08.2153"},{"key":"13054_CR65","doi-asserted-by":"publisher","unstructured":"Yin X, Wu J, Xu MD, Tian T, Zhu L, Wang J et al (2025) Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target. Mol Cancer 25(1). https:\/\/doi.org\/10.1186\/s12943-025-02502-8","DOI":"10.1186\/s12943-025-02502-8"},{"issue":"10","key":"13054_CR66","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00262-022-03182-9","volume":"71","author":"M Thibaudin","year":"2022","unstructured":"Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F (2022) Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. Cancer Immunol immunotherapy: CII 71(10):2549\u20132563. https:\/\/doi.org\/10.1007\/s00262-022-03182-9","journal-title":"Cancer Immunol immunotherapy: CII"},{"key":"13054_CR67","doi-asserted-by":"publisher","unstructured":"Farinea G, Anton-Pascual B, Catoya Villa JL, Riesco-Martinez MDC (2025) Change in MMR status as a mechanism of acquired resistance to immunotherapy in a dMMR colorectal cancer. BMJ case Rep 18(12). https:\/\/doi.org\/10.1136\/bcr-2024-264115","DOI":"10.1136\/bcr-2024-264115"},{"key":"13054_CR68","doi-asserted-by":"publisher","unstructured":"Randrian V, Evrard C, Tougeron D (2021) Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers 13(12). https:\/\/doi.org\/10.3390\/cancers13123063","DOI":"10.3390\/cancers13123063"},{"issue":"2","key":"13054_CR69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A et al (2017) Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations. Cancer Discov 7(2):188\u2013201. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1223","journal-title":"Cancer Discov"},{"issue":"4","key":"13054_CR70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","volume":"45","author":"C Zhang","year":"2022","unstructured":"Zhang C, Li D, Xiao B, Zhou C, Jiang W, Tang J et al (2022) B2M and JAK1\/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy. J Immunother 45(4):187\u2013193. https:\/\/doi.org\/10.1097\/CJI.0000000000000417","journal-title":"J Immunother"},{"issue":"6280","key":"13054_CR71","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463\u20131469. https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"issue":"12","key":"13054_CR72","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.xcrm.2024.101831","volume":"5","author":"JP Guegan","year":"2024","unstructured":"Guegan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E et al (2024) Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med 5(12):101831. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101831","journal-title":"Cell Rep Med"},{"issue":"8","key":"13054_CR73","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin oncology: official J Am Soc Clin Oncol 36(8):773\u2013779. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"13054_CR74","doi-asserted-by":"publisher","first-page":"goag009","DOI":"10.1093\/gastro\/goag009","volume":"14","author":"YC Yao","year":"2026","unstructured":"Yao YC, He MM, Wang M, Mo YX, Zhao Q, Jin Y et al (2026) Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study). Gastroenterol Rep 14:goag009. https:\/\/doi.org\/10.1093\/gastro\/goag009","journal-title":"Gastroenterol Rep"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13054-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-13054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T06:01:56Z","timestamp":1792908116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-13054-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["13054"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-13054-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"21 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors report no relevant conflicts of interest for this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approvals were not required for this systematic review, as it did not involve human participants or animals.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1801"}}